Completed PHASE4 INTERVENTIONAL 2-arm NCT00829465

Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma

Clinical Research of in the Treatment of Unresectable Hepatocellular Carcinoma

Sponsor: Eastern Hepatobiliary Surgery Hospital

Conditions Unresectable Hepatocellular Carcinoma

Interventions Licartin Transcatheter arterial chemoembolization

Updated 5 times since 2017 Last updated: Mar 30, 2016 Started: Dec 31, 2008 Primary completion: Dec 31, 2009 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Unresectable Hepatocellular Carcinoma, this trial is completed. The trial is conducted by Eastern Hepatobiliary Surgery Hospital and has accumulated 5 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Hepatobiliary Surgery Hospital

Data source: Eastern Hepatobiliary Surgery Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.